Needham Rates Nurix Therapeutics (NRIX) buy, $34 Price Target

Needham Maintains Optimism on Nurix Shares

Needham analyst Gil Blum reaffirmed a buy rating on Nurix Therapeutics, Inc. (NasdaqGM: NRIX) on June 15, 2026, holding firm on a $34.00 price target. That target sits far above where the equity currently changes hands, creating a wide spread that draws attention from growth-focused market participants. Blum's continued endorsement follows a steady stream of research updates from major investment banks tracking the biotechnology company.

Where the Stock Trades Today

Nurix shares recently changed hands at $17.43, well below their 52-week high of $28.23 and above the 52-week low of $8.20. The equity is currently navigating a path between its 50-day moving average of $25.20 and its 200-day moving average of $19.37. With a market capitalization near $2.64 billion, the biotechnology firm's valuation reflects significant expectations for its clinical pipeline even as the share price sits below its longer-term moving average.

Wall Street Analyst Coverage and Targets

A broad group of research firms continue to update their views on the biotechnology developer alongside Needham's stance. On October 16, 2026, HC Wainwright & Co. maintained a buy rating while setting a $36.00 target. Earlier on October 13, 2026, RBC Capital maintained an outperform rating with a $35.00 target, Oppenheimer kept its outperform rating with a $32.00 target, Truist Securities maintained a buy rating at a $33.00 target, and Baird maintained an outperform rating with a $36.00 target on the same day. Across fourteen analyst opinions, the company holds a mean price target of $33.93, with targets ranging from a low of $25.00 up to $45.00.

Insider Buying and Selling at Nurix Therapeutics, Inc.

In recent insider activity, Chief Scientific Officer Hansen Gwenn sold 1,452 shares of the company stock on October 15, 2026. The shares were sold at an average price of $25.00, for a total transaction value of $36,300.00. The trade was carried out under a pre-arranged Rule 10b5-1 trading plan, which allows corporate insiders to set up a schedule for selling shares ahead of time.

Inside the Clinical Pipeline

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule and antibody therapies for cancer, inflammatory conditions, and other diseases. The firm develops targeted protein degraders and inhibitors designed to address difficult biological targets in oncology and immunology, partnering with larger drug developers to advance multiple candidates through early-stage clinical trials.

Looking Ahead for NRIX

Market participants will continue to monitor updates from the company's clinical programs and any future research notes from Wall Street firms. Further insider filings and upcoming corporate updates will shape sentiment around the biotechnology developer as it works to advance its drug pipeline toward potential commercial milestones.